Bengaluru-based biotech startup Pandorum Technologies has raised $18 million (around ₹150 crore) in a Series B funding round, led by Protons Corporate, as it accelerates its push into global clinical and commercial markets.
The round saw participation from Galentic Pharma, investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, and members of the Burman Family, among others.
Two-Tranche Round Values Company at ₹822 Cr
The Series B round was completed in two tranches, with the first closed in November and the second in December. Following the fundraise, Pandorum is valued at approximately ₹822 crore ($91 million) on a post-money basis, according to estimates.
This marks a key milestone for the company as it transitions from a research-heavy phase to advanced clinical development and global scale-up.
Capital to Fund Clinical Expansion and Manufacturing Scale-Up
Pandorum said the fresh capital will be used to:
- Advance clinical-stage programmes
- Scale manufacturing infrastructure
- Expand market access across the US, Japan and the Middle East
- Strengthen regulatory, compliance and clinical capabilities
The company is focused on preparing its regenerative medicine platforms for late stage trials and eventual commercialisation in regulated global markets.
Focus on Regenerative and Exosome-Based Therapies
Founded by Tuhin Bhowmick and Arun Chandru, Pandorum operates in the regenerative medicine and biotechnology space.
The startup develops programmable, exosome based tissue regenerative therapies, targeting unmet medical needs through next-generation biologics. It currently operates across India and the United States.
Global Manufacturing Partnerships in Place
Pandorum follows a globally distributed manufacturing strategy to support its clinical and future commercial supply chain.
- In the US and Europe, the company has partnered with AGC Biologics
- For the Asia-Pacific region, it works with Nucelion Therapeutics, a subsidiary of Bharat Biotech
- Additional partnerships are being explored in the Middle East
These collaborations are aimed at ensuring regulatory-compliant supply at scale as Pandorum moves closer to commercial readiness.
Funding History and Financials
With the latest Series B round, Pandorum has raised around $43 million to date, including an $11 million Series A extension closed last year.
The company has not yet filed its FY25 financials. In FY24, Pandorum remained pre-revenue and reported losses of ₹28.2 crore, reflecting its continued investment in R&D and clinical development.
Outlook
The Series B funding positions Pandorum among a small but growing group of Indian biotech startups building globally relevant regenerative medicine platforms, as investor interest in deep-science and clinical stage companies continues to rise.
Follow Startupbydoc for daily startup insights, funding news, IPO analysis, and business breakdowns.